Antithrombotic actions of aspirin in the horse.

The research investigates the effects of aspirin on controlling blood clotting in horses, by changes in bleeding time and platelet aggregation. This study provides evidence that low doses of aspirin could be beneficial in preventing thrombosis in horses.

Study Overview

• The study was carried out using healthy ponies to examine the antithrombotic effects of two different dosages of aspirin (4 mg/kg and 11 mg/kg bodyweight).
• They used template bleeding time as a measure of the aspirin’s effectiveness.
• In addition, the research also assessed inhibition of platelet aggregation in response to adenosine diphosphate (ADP) and collagen stimulant.
• Cyclo-oxygenase activity was monitored by a radioimmunoassay of thromboxane B2 (TXB2), a stable metabolite of thromboxane A2 (TXA2).

Results and Findings

• The researchers found that aspirin significantly extended bleeding time for up to 48 hours after treatment at the higher dose rate. At the lower dose rate, this effect lasted up to 4 hours.
• Both TXB2 synthesis and collagen-induced aggregation were reduced for more extended periods, with similar results observed for each dose rate.
• These significant effects were observed even though aspirin has a very short plasma half-life. This is believed to be due to its irreversible impact on platelet cyclo-oxygenase.

Conclusions and Implications

• The results imply that low-dose aspirin has potential applications in antithrombotic therapy for horses. However, further research and clinical trials are needed to establish the relationship between skin bleeding time and clinical condition improvements.
• They suggest that measurement of TXB2 may overestimate the in vivo antithrombotic effects of aspirin over time.

Future Research

• The article concludes further research is required to validate the ability of TXB2 measurement to accurately determine the duration of aspirin’s antithrombotic effects.
• Furthermore, there is a need for more in-depth clinical trials to unveil the potential of low-dose aspirin as a routine antithrombotic therapeutic in equine medicine.